Background and Case Definition
A French medical-device company wants national market access in China for an imported patient-monitoring system. The product is approved in Europe, but China registration requires a defined product, classification, technical evidence, quality documentation and a responsible overseas registrant and China agent arrangement.
The scenario is illustrative. It removes a fictional company, product, eighteen-month approval claim and invented EUR 1.2 million budget. NMPA timing and evidence depend on classification, product complexity, testing, clinical route, dossier quality and regulatory questions. The company needs an evidence plan rather than a promised result.
Challenge: Freeze the Intended Use
Registration begins with intended use, indications, patient population, users, environment and claims. Marketing, clinical evidence, risk management and technical specifications must describe the same device. Expanding claims during review can change classification or evidence requirements.
The company defines the complete configuration: hardware, software, accessories, sensors, consumables and compatible systems. It controls model names and versions so products sold after approval match the registered materials. Optional functions are either included and supported or kept outside the China configuration.
Approach: Classification and Evidence Pathway
The regulatory team checks the Chinese classification catalogue and, where uncertainty remains, uses the available classification process. Class I devices generally follow filing, while Class II and III devices require registration under the applicable authority. Imported Class II and III products are handled through the national framework.
Foreign approval informs the dossier but does not replace Chinese classification or registration. The company identifies standards, type testing where applicable, clinical evaluation, clinical investigation, software and cybersecurity materials, labeling, manufacturing information and quality-system evidence.
Gap Assessment
A line-by-line comparison is made between the existing global technical file and Chinese requirements. Each missing or inconsistent item receives an owner and date. Common gaps include device description, essential principles, standards, test reports, clinical equivalence, software version records, cybersecurity, shelf life, packaging, transport validation and Chinese labeling.
Translation is controlled as regulatory content, not an administrative afterthought. Terminology, units, model names and claims remain consistent across forms, reports, instructions and labels. Technical reviewers participate in quality control of translated materials.
Testing Strategy
The team identifies applicable Chinese standards and confirms the test route before samples are built and shipped. Product configuration, accessories and software used for testing are recorded. Changes after testing are assessed for their effect on validity.
Sample import, customs, test-laboratory scheduling, failure investigation and retest are included in the project plan. A generic estimate cannot substitute for quotations and acceptance from the laboratory that will perform the work.
Clinical Evidence
The company determines whether clinical evaluation can rely on existing evidence and comparison or whether a clinical investigation is required. The analysis considers product characteristics, risk, differences from predicates, population and intended use. A CE mark does not automatically answer the Chinese clinical question.
Where a study is needed, sites, ethics, protocol, endpoints, data management, monitoring, statistics and device accountability are planned under the applicable Chinese requirements. Where overseas data are used, relevance and quality are demonstrated rather than assumed.
Overseas Registrant and China Agent
The overseas manufacturer retains substantive responsibilities for product safety, quality, changes and post-market action. The designated China agent performs required local functions and communications. The contract gives the manufacturer access to submissions, authority correspondence, complaints and adverse-event information.
The agent should not control the only copy of the dossier or registration account. Roles for importer, distributor and service provider are separated from regulatory responsibility. If the commercial partner changes, the company must be able to maintain compliance and continuity.
Review and Deficiency Management
A single project team coordinates regulatory, clinical, engineering, quality and China commercial functions. Questions from the authority are logged with the underlying issue, evidence, owner and deadline. Responses address the technical concern consistently across affected documents.
Management protects review time from uncontrolled design and marketing changes. Necessary changes are documented and their registration effect assessed. Commercial pressure does not justify submitting unsupported data or contradictory claims.
Post-Approval Readiness
Approval is followed by import, labeling, distribution, installation, training, maintenance, complaint, adverse-event, recall and change-control obligations. The company qualifies distributors and service providers before launch and ensures reportable information reaches the responsible teams.
Software updates, supplier changes, manufacturing changes and new claims are reviewed for regulatory action before release. China product configuration remains linked to the approved dossier and global quality system.
Labeling, Import and Commercial Release
Chinese labels and instructions are controlled components of the approved product. Model, registrant, agent, specifications, warnings, storage and use information must remain consistent with the registration. Importer and distributor master data should prevent an unapproved model or language version from entering the channel.
Commercial release requires more than a registration certificate. Inventory, customs documents, installation records, user training, spare parts, complaint channels and field-service escalation must be operational. The sales team should understand approved indications and avoid claims that expand intended use.
Reimbursement and Procurement Assessment
The company evaluates how target hospitals purchase and fund the product, including tendering, department budgets, consumable economics and any relevant centralized procurement policy. Registration permits market access but does not establish reimbursement or tender success. Distributor forecasts are tested against named institutions, procurement steps and clinical users.
Price planning includes import cost, tax, channel margin, demonstration units, service, payment terms and post-market obligations. A technically successful registration can still be a poor investment if the commercial model cannot support safe installation and continuing service.
Management Lessons for Project Governance and Budget
The project budget separates authority fees, testing, samples, translation, clinical evidence, agent, consulting, travel, personnel and contingency. Decision gates are tied to classification, testing feasibility, clinical pathway and commercial demand. Management does not present one case budget as a universal benchmark.
A credible schedule is built from the specific evidence path and external dependencies. The board receives ranges and risks rather than a guaranteed eighteen-month approval date. A stop decision remains available if the required evidence or market opportunity no longer supports investment.
Result: Evidence-Based Registration Decision
The company proceeds after intended use, classification, testing and clinical pathways are documented and the China commercial case can support post-market obligations. The registration plan is an evidence program with controlled product configuration, not an accelerated paperwork exercise.
Official Sources
- National Health Commission: Regulations for the Supervision and Administration of Medical Devices
- National Medical Products Administration: Measures for Medical Device Registration and Filing
- National Medical Products Administration: medical-device rules and guidance portal
- Cyberspace Administration of China: cross-border data flow provisions
